|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
National Cancer Institute: SEER Cancer Statistics Review, 1975-2016. https://seer.cancer.gov/archive/csr/1975_2016/. Accessed: June 30, 2020.
|
|
3
|
de Melo Gagliato D, C Buzaid A, Perez-Garcia JM, Llombart A and Cortes J: CDK4/6 Inhibitors in hormone receptor-positive metastatic breast cancer: Current practice and knowledge. Cancers (Basel). 12(2480)2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
U.S. Food and Drug: FDA approves abemaciclib as initial therapy for HR-positive, HER2-negative metastatic breast cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abemaciclib-initial-therapy-hr-positive-her2-negative-metastatic-breast-cancer. Accessed March 27, 2021.
|
|
5
|
U.S. Food and Drug: FDA apporves palbociclib as a treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women; https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance. Accessed March 27, 2021.
|
|
6
|
U.S. Food and Drug: FDA approved ribociclib, a cyclin-dependent kinase 4/6 inhibitor, in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer; https://www.fda.gov/drugs/resources-information-approved-drugs/ribociclib-kisqali. Accessed March 27, 2021.
|
|
7
|
European Medicine Agency (EMA): EMA approval of palbociclib; https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance. Accessed March 27, 2021.
|
|
8
|
European Medicine Agency (EMA): EMA approval of ribociclib; https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali. Accessed March 27, 2021.
|
|
9
|
European Medicine Agency (EMA): EMA approval of abemaciclib; https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios. Accessed March 27, 2021.
|
|
10
|
Saudi FDA: Approval and registration of palbociclib; https://sdi.sfda.gov.sa/Home/Result?drugId=7121. Accessed March 28, 2021.
|
|
11
|
Saudi FDA: Approval and registration of ribociclib; https://sdi.sfda.gov.sa/Home/Result?drugId=7956. Accessed March 28, 2021.
|
|
12
|
Saudi FDA: Approval and registration of abemaciclib; https://sdi.sfda.gov.sa/Home/Result?drugId=8132. Accessed March 28, 2021.
|
|
13
|
Piezzo M, Cocco S, Caputo R, Cianniello D, Gioia GD, Lauro VD, Fusco G, Martinelli C, Nuzzo F, Pensabene M and Laurentiis M: Targeting cell cycle in breast cancer: CDK4/6 inhibitors. Int J Mol Sci. 21(6479)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Chen X, Xu D, Li X, Zhang J, Xu W, Hou J, Zhang W and Tang J: Latest overview of the cyclin-dependent kinases 4/6 inhibitors in breast cancer: The past, the present and the future. J Cancer. 10:6608–6617. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gao JJ, Cheng J, Bloomquist E, Sanchez J, Wedam SB, Singh H, Amiri-Kordestani L, Ibrahim A, Sridhara R, Goldberg KB, et al: CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: A US food and drug administration pooled analysis. Lancet Oncol. 21:250–260. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, et al: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 29:1541–1547. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, et al: Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial. Lancet Oncol. 19:904–915. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hurvitz SA, Im SA, Lu YS, Colleoni M, Franke FA, Bardia A, Harbeck N, Chow L, Sohn J, Lee KS, et al: Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2-advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. J Clin Oncol. 37(LBA1008)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, et al: Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 36:2465–2472. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martin M, et al: Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). Ann Oncol. 30:V856–V857. 2019.
|
|
21
|
Slamon DJ, Neven P, Chia SKL, Im SA, Fasching PA, DeLaurentiis M, Petrakova K, Bianchi GV, Esteva FJ, Martin M, et al: Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3. J Clin Oncol. 36(1000)2018.
|
|
22
|
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, et al: Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 382:514–524. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lu YS, Bardia A, Vázquez RV, Colleoni MA, Wheatley-Price P, Im YH, Babu G, Tripathy D, Lanoue BR, Chandiwana D, et al: Updated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or placebo (PBO) plus goserelin and a nonsteroidal aromatase inhibitor (NSAI) in the MONALEESA-7 (ML-7) trial. Ann Oncol. 30(V106)2019.
|
|
24
|
Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, et al: Overall Survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 381:307–316. 2019.
|
|
25
|
Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, et al: MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer. Ann Oncol. 30(V856)2019.
|
|
26
|
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, et al: The Effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A randomized clinical trial. JAMA Oncol. 6:116–124. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Spring LM, Wander SA, Andre F, Moy B, Turner NC and Bardia A: Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: Past, present, and future. Lancet. 395:817–827. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Breast cancer drug Verzenio could have serious side effects on lungs Js health ministry warns. The Japan Times. 17 May, 2019.
|
|
29
|
U.S. Food and Drug: FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-severe-lung-inflammation-ibrance-kisqali-and-verzenio-breast-cancer. Accessed September 9, 2019.
|
|
30
|
Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, et al: Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, Node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 38:3987–3998. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
American Heart Association: Classes of Heart Failure; https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure. Accessed March 27, 2021.
|
|
32
|
American Thoracic Society: 2017 ERS/ATS standards for single-breathcarbon monoxide uptake in the lung; https://www.thoracic.org/statements/resources/pft/DLCO.pdf. Accessed March 27, 2021.
|
|
33
|
Omarini C, Thanopoulou E and Johnston SR: Pneumonitis and pulmonary fibrosis associated with breast cancer treatments. Breast Cancer Res Treat. 146:245–258. 2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, et al: Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 375:1925–1936. 2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ahsan I, Malik F and Jafri SI: Palbociclib related pnemotoxicity: A rare side effect. In: C43. Drug Induced Lung Disease: Case Reports, ppA5546, 2017.
|
|
36
|
Azhar A, Zaman K and Samad R: A tale of unexplained pneumotoxicity: The dangers of palbociclib. In: B36. Case Reports in Biologic and Chemotherapeutic Agent Induced Lung Disease, ppA3120, 2020.
|
|
37
|
Felip E, Llobera L, Perez-Mañá C, Quintela D, Guasch I, Margelí M, Teruel I, Cirauqui B, Centeno C, Romeo M, et al: New drugs, old toxicities: Pneumonitis related to palbociclib-a case report. Breast Care. 15:548–552. 2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Gong J, Cho M, Yu KW, Waisman J, Yuan Y and Mortimer J: A single institution experience with palbociclib toxicity requiring dose modifications. Breast Cancer Res Treat. 168:381–387. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Jazieh KA, Budd GT, Dalpiaz N and Abraham J: Can CDK4/6 inhibitors cause fatal lung injury? Expert Rev Anticancer Ther. 19:917–919. 2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Levy O, Ptashkin E, Shechtman Y, Kas T, Natif N, Sanset S and Katz D: Fatal palbociclib-related interstitial pneumonitis. Arch Clin Med Case Rep. 3:162–166. 2019.
|
|
41
|
Okura F, Sato Y, Murakami E, Komatsu H, Yamamura Y and Ito Y: A case of interstitial pneumonitis induced by palbociclib. Gan To Kagaku Ryoho. 47:997–999. 2020.PubMed/NCBI(In Japanese).
|
|
42
|
Sarkisian S, Markosian C, Ali Z and Rizvi M: Palbociclib-induced pneumonitis: A case report and review of the literature. Cureus. 12:e8929. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Algwaiz G, Badran AA, Elshenawy MA and Al-Tweigeri T: Ribociclib-induced pneumonitis: A case report. Breast Care: https://doi.org/10.1159/000507647.
|
|
44
|
Liu A: Lilly oncology suffers another blow as Verzenio slapped with safety warning in Japan. Fierce Pharma, 2019. https://www.fiercepharma.com/pharma/lilly-oncology-suffers-another-blow-as-verzenio-slapped-safety-warning-japan. Accessed May 21, 2019.
|
|
45
|
Eli Lilly and Company: Abemaciclib (Verzenio R) US prescribing information. http://pi.lilly.com/us/verzenio-uspi.pdf. Accessed September 2019.
|
|
46
|
Rugo HS, Huober J, García-Sáenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J and Goetz M: Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Safety analysis of MONARCH 2 and MONARCH 3. Oncologist. 26:e522. 2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Chuzi S, Tavora F, Cruz M, Costa R, Chae YK, Carneiro BA and Giles FJ: Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res. 9:207–213. 2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Kawajiri H, Takashima T, Onoda N, Kashiwagi S, Ishikawa T and Hirakawa K: Interstitial pneumonia associated with neoadjuvant chemotherapy in breast cancer. Mol Clin Oncol. 1:433–436. 2013.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Bielopolski D, Evron E, Moreh-Rahav O, Landes M, Stemmer SM and Salamon F: Paclitaxel-induced pneumonitis in patients with breast cancer: Case series and review of the literature. J Chemother. 29:113–117. 2017.PubMed/NCBI View Article : Google Scholar
|
